factually
Index/Organizations/TRAILBLAZER-ALZ2

TRAILBLAZER-ALZ2

Fact-Checks

2 results
Feb 1, 2026
Most Viewed

How have recent Phase III anti‑amyloid readouts correlated amyloid plaque reduction with clinical benefit?

Recent Phase III readouts show a clear group‑level relationship: antibodies that produce large, sustained reductions in amyloid PET signal have tended to produce modest but statistically significant s...

Feb 7, 2026

Which patient subgroups (tau burden, APOE4 status, clinical stage) show the largest benefit from donanemab or lecanemab in trial subgroup analyses?

shows its clearest, largest subgroup benefit in patients with low-to-medium baseline burden (the “earlier” tau stage), with subgroup analyses reporting roughly one-third slower clinical decline and hi...